CAS: 41001-90-5; Hesperetin

上下游产品

hesperidin G-α-D-glucopyranosyl hesperidin4G-α-D-glucopyranosyl hesperidin (S)-2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone methanol5-hydroxy-3′4′7-trimethoxy flavanone S)-5,7-diacetoxy-2-(3-acetoxy-4-methoxy-phenyl)-chroman-4-one(S)-5,7-diacetoxy-2-(3-acetoxy-4-methoxy-phenyl)-chroman-4-one (-)-hesperetin oxime Hesperetin 7-O-sulfate

专利信息

专利号:WO-2025081225-A1
优先权日:2023-10-17
标 题 :Synthesis of polyphenols
发明人：TURLAND CADE LACHLAN; GROLMAN DAVID; BEHRENDORFF JAMES BRUCE YARNTON HAYCOCK; MORADI SHAYLI VARASTEH; THOMSON RAINE ELIZABETH STURT
权利人:Delica Therapeutics Pty Ltd
摘要:The present disclosure relates to polyphenols, including flavonoids, flavones and cannflavins, and methods of synthesising polyphenols. The present disclosure provides methods, enzymes and compositions that may be useful in the synthesis of polyphenols.

专利号:US-9149659-B2
优先权日:2012-11-14
标题 :Cosmetic composition for increasing hyaluronic acid synthesis in skin and its use for repairing wrinkles
发明人：PUJOS MURIEL; BERNINI DOROTHEE; ROBERT CECILE; DOUCET OLIVIER
权利人:COTY GERMANY GMBH
摘要:The present invention relates to a skin composition which has an excellent effect on smoothing or repairing wrinkles. The composition comprises Palmitoyl Tripeptide-38 (Palmitoyl-Lysyl-Dioxymethionyl-Lysine) and Piper nigrum (Pepper) seed Extract which combination has been found to result in a synergistic effect on hyaluronan synthase 1 (HAS1) mRNA expression in human fibroblasts. The hyaluronan synthase is responsible for the synthesis of hyaluronan (hyaluronic acid) in skin. Hyaluronic acid is a constituent of the extracellular matrix of the skin and responsible for space filling, tissue repair and retention of moisture.

专利号:US-2002165207-A1
优先权日:2001-05-02
标题 :Compositions and methods for the treatment of diabetic neuropathy
发明人：ROSENBLOOM RICHARD
摘要:Compositions and a method for the treatment of diabetic neuropathy is disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.

专利号:US-2024026314-A1
优先权日:2020-11-25
标题 :Polypeptides for use in the synthesis of bioactive phenolic compounds
发明人：ROTHSTEIN STEVEN; AKHTAR TARIQ; CASARETTO JOSE; PERRIN COLBY; VAN GELDER KRISTEN
权利人:ROTHSTEIN STEVEN; AKHTAR TARIQ; CASARETTO JOSE; PERRIN COLBY; VAN GELDER KRISTEN
摘要:Described herein is a polypeptide encoding a prenyltransferase for prenylating a polyphenol and a polypeptide encoding an O-methyltransferase for methylating a polyphenol. For example, the polypeptide comprises or consists of the sequence of SEQ ID NO: 1, 2, 3, 4, 5, and/or 6, and/or a polypeptide listed in Table 1, and/or SEQ ID NO: 7-30, or a variant thereof having at least 80% sequence identity to SEQ ID NO: 1, 2, 3, 4, 5, and/or 6, and/or the polypeptide listed in Table 1, and/or SEQ ID NO: 7-30, or a fragment of the polypeptide or the variant thereof.

专利号:US-7914823-B2
优先权日:2000-12-21
标题 :Method and composition for the topical treatment of diabetic neuropathy
发明人：ROSENBLOOM RICHARD ALLEN
权利人:PROPHASE LABS INC
摘要:A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recovery of the damaged nerve tissues.

专利号:EP-1351679-B1
优先权日:2000-12-21
标题 :Method and composition for the treatment of diabetic neuropathy
发明人：ROSENBLOOM RICHARD A
权利人:THE QUIGLEY CORP
摘要:Compositions and a method for the treatment of diabetic neuropathy are disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.